Published in Clin Cancer Res on February 02, 2016
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol (2014) 8.48
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med (2014) 4.81
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
Cytokines in inflammatory bowel disease. Nat Rev Immunol (2014) 3.24
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05
Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene (2003) 2.51
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood (2001) 2.40
Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci U S A (1990) 2.25
The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J (2001) 2.21
Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res (2003) 2.18
IL-6 as a keystone cytokine in health and disease. Nat Immunol (2015) 2.14
Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci U S A (2014) 2.12
Interleukin 6 and haemostasis. Br J Haematol (2001) 1.75
Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol (1997) 1.65
Interleukin-6--a key regulator of colorectal cancer development. Int J Biol Sci (2012) 1.65
STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res (2011) 1.63
Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol (2006) 1.52
Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J Immunol (2010) 1.39
IL6 genotypes and colon and rectal cancer. Cancer Causes Control (2007) 1.36
Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br J Cancer (2013) 1.34
Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension (2011) 1.29
Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways. Mutat Res (2008) 1.18
-174 G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res (2003) 1.05
Interleukin-6: an angiogenic target in solid tumours. Crit Rev Oncol Hematol (2013) 1.03
Interleukin 6 alters localization of hMSH3, leading to DNA mismatch repair defects in colorectal cancer cells. Gastroenterology (2014) 1.01
Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis (2008) 1.01
Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients. Clin Exp Immunol (2014) 0.98
Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma. Br J Cancer (2013) 0.97
Novel mechanism of macrophage-mediated metastasis revealed in a zebrafish model of tumor development. Cancer Res (2014) 0.93
Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins. BMC Cancer (2011) 0.93
Relationship between expression and prognostic ability of PTEN, STAT3 and VEGF-C in colorectal cancer. Exp Ther Med (2012) 0.92
Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition. Carcinogenesis (2015) 0.91
Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner. BMC Cancer (2014) 0.91
Prognostic value of phosphorylated STAT3 in advanced rectal cancer: a study from 104 French patients included in the EORTC 22921 trial. J Clin Pathol (2010) 0.90
IL6 gene polymorphisms and susceptibility to colorectal cancer: a meta-analysis and review. Mol Biol Rep (2012) 0.90
Interleukin-6 Stimulates Defective Angiogenesis. Cancer Res (2015) 0.90
Polymorphisms of the Interleukin 6 gene contribute to cervical cancer susceptibility in Eastern Chinese women. Hum Genet (2012) 0.89
PTTG acts as a STAT3 target gene for colorectal cancer cell growth and motility. Oncogene (2013) 0.88
Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis. J Biol Chem (2015) 0.84
Identification of a functional EGF-R/p60c-src/STAT3 pathway in colorectal carcinoma: analysis of its long-term prognostic value. Cancer Biomark (2008) 0.83
Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. Pharmacogenomics J (2014) 0.83
IL-6-174 G > C and MMP-9-1562 C > T polymorphisms are associated with increased risk of deep vein thrombosis in cancer patients. Cytokine (2013) 0.82
IL6 Mediates Immune and Colorectal Cancer Cell Cross-talk via miR-21 and miR-29b. Mol Cancer Res (2015) 0.81
Association of interleukin-6 polymorphisms with susceptibility to hepatocellular carcinoma. Int J Clin Exp Med (2015) 0.81
Association of serum and intratumoral cytokine profiles with tumor stage and neutrophil lymphocyte ratio in colorectal cancer. Anticancer Res (2014) 0.81
Interleukin-6, but not the interleukin-6 receptor plays a role in recovery from dextran sodium sulfate-induced colitis. Int J Mol Med (2014) 0.80
Association between STAT3 polymorphisms and cancer risk: a meta-analysis. Mol Genet Genomics (2015) 0.77
Expressional STAT3/STAT5 Ratio is an Independent Prognostic Marker in Colon Carcinoma. Ann Surg Oncol (2015) 0.77
Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. Cancer (2015) 1.42
Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment. Clin Cancer Res (2016) 0.82
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Oncotarget (2015) 0.81
FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply. Lancet Oncol (2014) 0.78
TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy. Mol Cancer Ther (2016) 0.75